Eli Lilly Says New England Journal Of Medicine Publishes BRUIN Phase 1/2 Trial Data For Pirtobrutinib
Portfolio Pulse from Benzinga Newsdesk
The New England Journal of Medicine has published detailed results from the BRUIN Phase 1/2 trial evaluating the efficacy and safety of pirtobrutinib, a drug under investigation by Eli Lilly. The drug, a non-covalent Bruton's tyrosine kinase inhibitor, is being tested in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were previously treated with a BTK inhibitor.
July 06, 2023 | 11:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's investigational drug pirtobrutinib has had its BRUIN Phase 1/2 trial results published in the New England Journal of Medicine. The drug is being tested for use in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
The publication of trial results in a prestigious journal like the New England Journal of Medicine is a positive development for Eli Lilly. It suggests that the drug has shown promising results in the trial, which could potentially lead to regulatory approval and commercialization. This could have a positive impact on Eli Lilly's stock in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100